Dr. Usmani on the Gimema-MMY-3006 Study for Multiple Myeloma

Saad Z. Usmani, MD
Published: Thursday, Dec 21, 2017



Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the phase III Gimema-MMY-3006 study for patients with multiple myeloma.

MMprofiler is a gene expression profiling tool that is going to be commercialized in the United States, explains Usmani. The Gimema-MMY-3006 study investigated MMprofiler with SKY92 for patients with high- and low-risk of relapse.

SKY92 can independently prognosticate patients who are at the highest risk for disease relapse. According to Usmani, the field is at the point where there is a better prognostication as well as molecular subclass identification of myeloma with gene expression profiling.
 


Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the phase III Gimema-MMY-3006 study for patients with multiple myeloma.

MMprofiler is a gene expression profiling tool that is going to be commercialized in the United States, explains Usmani. The Gimema-MMY-3006 study investigated MMprofiler with SKY92 for patients with high- and low-risk of relapse.

SKY92 can independently prognosticate patients who are at the highest risk for disease relapse. According to Usmani, the field is at the point where there is a better prognostication as well as molecular subclass identification of myeloma with gene expression profiling.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x